Amanta Healthcar Q2 FY27 Results (NSE: AMANTA)
Signal: Growth reaccelerated
The read
The trajectory is shifting from low-growth operations to capacity-led expansion: Q2FY27 revenue grew 17.3% to ₹83.13 crore and EBITDA margin improved 80bps to 21.6%, with SteriPort Line 3 lifting capacity 75% to 11.6 crore bottles; however, finance cost rose 13.4% to ₹5.84 crore and PAT growth is inflated by the absence of the ₹2.63 crore prior-year exceptional item.
| Metric | Value | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹83.13 Cr | +17.3% | +20.8% |
| Net profit | ₹4.86 Cr | +301.7% | |
| EBIT margin | 21.6% |
P&L walk
Standalone Q2FY27 revenue rose 17.3% to ₹83.13 crore on price increases and new-line sales; EBITDA grew 21.9% to ₹17.95 crore with margin expanding 80bps as other expenses fell 4.5%, while finance cost rose 13.4% to ₹5.84 crore and PAT benefited from the absence of the ₹2.63 crore exceptional item recorded in Q2FY26.
Key positives
- Revenue rose 17.3% YoY to ₹83.13 crore, accelerating from the 5.4% YoY growth reported for Q1FY27, with the filing attributing growth to price increases and new-line sales.
- EBITDA increased 21.9% YoY to ₹17.95 crore and EBITDA margin expanded 80bps to 21.6% as other expenses declined 4.5% YoY.
- SteriPort Line 3 was commissioned in September 2026, increasing capacity 75% from 6.6 crore to 11.6 crore bottles and carrying expected FY27 revenue contribution of ~₹60 crore.
- The 10.8 MW captive solar plant has been operational since the end of Q1FY27 and is expected to deliver around ₹9 crore of annual savings.
Key concerns
- Finance cost rose 13.4% YoY to ₹5.84 crore, limiting conversion of EBITDA growth into recurring earnings.
- Q2FY27 PAT of ₹4.86 crore versus ₹1.21 crore implies 301.7% YoY growth, but the comparison is distorted by the ₹2.63 crore exceptional item in Q2FY26.
- The filing contains inconsistent PAT-growth disclosures: the headline cites 26% Q2 PAT growth, while the reported Q2 PAT values imply 301.7% growth and H1 PAT of ₹8.17 crore versus ₹4.71 crore implies 73.5% growth rather than the stated 12%.
Research and educational content only. Not investment advice.